No abstract

Summary The use of bretylium tosylate in hypertensive pregnant women is discussed. Using C‐14 labelled material there is evidence of placental transfer but this does not appear to affect the foetus adversely. In 12 patients, Darenthin adequately controlled the blood pressure of both essential hypertension complicating pregnancy and pre‐eclampsia. There is insufficient evidence to show whether or not this control improves foetal prognosis or modifies other manifestations of toxaemia. In 1 patient, therapy was discontinued because of severe urticaria.

No abstract